Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

1. Non-invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients. (PubMed)

Non-invasive positive pressure ventilation for prevention of complications after pulmonary resection in lung cancer patients. BACKGROUND: Pulmonary complications are often seen during the postoperative period following lung resection for patients with lung cancer. Some situations such as intubation, a long stay in the intensive care unit, the high cost of antibiotics and mortality may be avoided with the prevention of postoperative pulmonary complications. Non-invasive positive (...) pressure ventilation (NIPPV) is widely used in hospitals, and is thought to reduce the number of pulmonary complications and mortality after this type of surgery. Therefore, a systematic review is needed to critically assess the benefits and harms of NIPPV for patients undergoing lung resection. This is an update of a Cochrane review first published in 2015. OBJECTIVES: To assess the effectiveness and safety of NIPPV for preventing complications in patients following pulmonary resection for lung cancer. SEARCH METHODS

2019 Cochrane

2. Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal)

Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) Dabr Dabrafenib with tr afenib with trametinib for treating ametinib for treating advanced metastatic BRAF V600E advanced metastatic BRAF V600E mutation-positiv mutation-positive non-small-cell lung e non-small-cell lung cancer (terminated appr cancer (terminated appraisal) aisal) T echnology appraisal guidance Published: 27 February 2019 nice.org.uk (...) /guidance/ta564 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Contents Contents Advice 3 Information 3 Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non- small-cell lung cancer (terminated appraisal) (TA564) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 3Advice Advice NICE is unable to make

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

3. Crizotinib (Alunbrig) - for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)

Crizotinib (Alunbrig) - for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization

2019 Health Canada - Drug and Health Product Register

4. Short-Term Readmissions After Open, Thoracoscopic, and Robotic Lobectomy for Lung Cancer Based on the Nationwide Readmissions Database

Short-Term Readmissions After Open, Thoracoscopic, and Robotic Lobectomy for Lung Cancer Based on the Nationwide Readmissions Database 30603764 2019 01 03 1432-2323 2019 Jan 02 World journal of surgery World J Surg Short-Term Readmissions After Open, Thoracoscopic, and Robotic Lobectomy for Lung Cancer Based on the Nationwide Readmissions Database. 10.1007/s00268-018-04900-0 Readmission after surgery is an established surrogate indicator of quality of care. We aimed to compare short-term (...) readmission rates and patient outcomes between open, video-assisted thoracoscopic (VATS), and robotic lobectomies in the Nationwide Readmissions Database (NRD). Adults who underwent open, VATS, or robotic lobectomy for lung cancer from 2010 to 2014 were evaluated. Propensity-matched analysis was used to assess differences in readmission characteristics, GDP-adjusted cost, and mortality. Of the 129,539 lobectomies for lung cancer, 74,493 (57.5%) were open, 48,185 (37.2%) VATS, and 6861 (5.3%) robotic. Open

2019 EvidenceUpdates

5. Whole brain radiotherapy provides little benefit for lung cancer that has spread

Whole brain radiotherapy provides little benefit for lung cancer that has spread Signal - Whole brain radiotherapy provides little benefit for lung cancer that has spread Dissemination Centre Discover Portal NIHR DC Discover Whole brain radiotherapy provides little benefit for lung cancer that has spread Published on 10 January 2017 Radiotherapy to the whole brain makes little difference to people with the commonest type of lung cancer that has spread to the brain and cannot be operated (...) on. This mainly UK-based trial found no difference in overall survival and quality of life among people who had whole brain radiotherapy plus usual supportive care compared with people who received supportive care alone. This is the largest trial to assess the effect of this treatment in people with non-small cell lung cancer and multiple brain metastases (cancer deposits in the brain). Practice has been changing since early results of the trial were released. The final results reinforce the message

2019 NIHR Dissemination Centre

6. Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer

Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer Signal - Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer Dissemination Centre Discover Portal NIHR DC Discover Postoperative radiotherapy reduces survival after surgery to remove non-small cell lung cancer Published on 28 February 2017 Postoperative radiotherapy increases the risk of death by 18% for patients with non-small cell lung cancer that has been (...) on survival and cancer recurrence rates. Most of the trials are from over 30 years ago, so there is the possibility that newer radiotherapy techniques may be less harmful. Nevertheless, this review provides the best evidence to date that postoperative radiotherapy may not be appropriate as a routine treatment for non-small cell lung cancer. Share your views on the research. Why was this study needed? Lung cancer is the second most common cancer in the UK with 37,453 new cases registered in 2014

2019 NIHR Dissemination Centre

7. Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: nested case-control study within Lung Cancer Cohort Consortium. (PubMed)

Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: nested case-control study within Lung Cancer Cohort Consortium. OBJECTIVES: To conduct a comprehensive analysis of prospectively measured circulating high sensitivity C reactive protein (hsCRP) concentration and risk of lung cancer overall, by smoking status (never, former, and current smokers), and histological sub-type. DESIGN: Nested case-control study. SETTING: 20 population based cohort studies in Asia (...) , Europe, Australia, and the United States. PARTICIPANTS: 5299 patients with incident lung cancer, with individually incidence density matched controls. EXPOSURE: Circulating hsCRP concentrations in prediagnostic serum or plasma samples. MAIN OUTCOME MEASURE: Incident lung cancer diagnosis. RESULTS: A positive association between circulating hsCRP concentration and the risk of lung cancer for current (odds ratio associated with a doubling in hsCRP concentration 1.09, 95% confidence interval 1.05

2019 BMJ

8. A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer

A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer 30482524 2018 12 18 1097-685X 157 1 2019 Jan The Journal of thoracic and cardiovascular surgery J. Thorac. Cardiovasc. Surg. A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer. 362-373.e8 S0022-5223(18)32347-X 10.1016/j.jtcvs.2018.08.075 Stereotactic body radiation (...) therapy is the preferred treatment modality for patients with inoperable early-stage non-small cell lung cancer. However, comparative outcomes between stereotactic body radiation therapy and surgery for high-risk patients remain controversial. The primary aim of the present meta-analysis was to assess overall survival in matched and unmatched patient cohorts undergoing stereotactic body radiation therapy or surgery. Secondary end points included cancer-specific survival, disease-free survival, disease recurrence

2019 EvidenceUpdates

9. Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer P Pembrolizumab with pemetre embrolizumab with pemetrex xed and ed and platinum chemother platinum chemotherap apy for untreated, y for untreated, metastatic, non-squamous non-small-cell metastatic, non-squamous non-small-cell lung cancer lung cancer T echnology appraisal guidance Published: 10 January 2019 nice.org.uk/guidance/ta557 © NICE 2019. All rights reserved (...) -small-cell lung cancer (TA557) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 23Contents Contents 1 Recommendations 4 2 Information about pembrolizumab combination 6 3 Committee discussion 7 Clinical management 7 Clinical evidence 8 Indirect treatment comparisons 9 Cost effectiveness 11 Innovation 16 End of life 17 Conclusion 18 Cancer Drugs Fund 18 4 Implementation 20 5 Recommendations for data collection 21

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

10. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer 1 Special Article Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer; a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS Authors Y-L. Wu 1 , D. Planchard 2 , S. Lu 3 , H. Sun 4 , N. Yamamoto 5 , D-W. Kim 6 , D. S. W. Tan 7 , J. C-H. Yang 8 , M. Azrif 9 , T. Mitsudomi 10 , K. Park 11 , R (...) . A. Soo 12 , J.W.C. Chang 13 , A. Alip 14 , S. Peters 15 , J-Y. Douillard 16 Affiliations 1 Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, P.R. China; 2 Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif, France; 3 Shanghai Chest Hospital, Shanghai, P.R. China; 4 Guangdong Lung Cancer Institute, Guangdong Lung Cancer Institute, Guangdong General Hospital, School of Medicine, South China University of Technology

2019 European Society for Medical Oncology

11. ASTRO Guideline on Palliative Radiation Therapy for Non-small Cell Lung Cancer (NSCLC) - Update

ASTRO Guideline on Palliative Radiation Therapy for Non-small Cell Lung Cancer (NSCLC) - Update Practical Radiation Oncology Email/Username: Password: Remember me Search Terms Search within Search Share this page: Copyright © 2019 Inc. All rights reserved. | | | | | | The content on this site is intended for health professionals. We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the . Advertisements on this site do not constitute

2019 American Society for Radiation Oncology

12. Impact of breathing exercises in subjects with lung cancer undergoing surgical resection: A systematic review and meta-analysis

Impact of breathing exercises in subjects with lung cancer undergoing surgical resection: A systematic review and meta-analysis 30357997 2018 11 21 1365-2702 2018 Oct 24 Journal of clinical nursing J Clin Nurs Impact of breathing exercises in subjects with lung cancer undergoing surgical resection: A systematic review and meta-analysis. 10.1111/jocn.14696 To assess the effects of breathing exercises on postoperative pulmonary complications (PPCs), pulmonary function, 6-min walk distance (6MWD (...) ) and the length of hospital stay (LOS) in lung cancer patients undergoing lung surgery. Lung cancer patients undergoing lung resection have poor pulmonary function and multiple PPCs. Breathing exercises may improve these symptoms. Systematic literature review and meta-analysis were conducted. All entries to the following databases were searched up until 20 December 2017: PubMed, EMBASE Ovid, the Cochrane Central Register of Randomized Controlled Trials, Web of Science, Wanfang, Weipu and Chinese National

2019 EvidenceUpdates

13. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. (PubMed)

Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. 30666799 2019 01 22 1759-7714 2019 Jan 21 Thoracic cancer Thorac Cancer Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. 10.1111/1759-7714.12977 Anlotinib is an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet (...) -derived growth factor receptor, and stem cell factor receptor (c-Kit). In the phase III ALTER-0303 trial (Clinical Trial Registry ID: NCT 02388919), anlotinib significantly improved overall survival versus placebo in advanced non-small cell lung cancer patients who had received at least two previous chemotherapy and epidermal growth factor receptor/anaplastic lymphoma kinase targeted therapy regimens. This study summarized adverse event management in this trial. Patients were randomized (2:1

Full Text available with Trip Pro

2019 Thoracic cancer

14. Alectinib (Alecensa) for the treatment of patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

Alectinib (Alecensa) for the treatment of patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) 1 Cost-effectiveness of alectinib (Alecensa®) for the first line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung carcinoma (NSCLC) The NCPE has issued a recommendation regarding the cost-effectiveness of alectinib (Alecensa®). Following assessment of the applicant’s submission, the NCPE recommends (...) lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). At the same time, they also converted the conditional marketing authorisation to a standard marketing authorisation for the crizotinib failure indication (2L) which had been approved in the EU since February 2017. In April 2018, Roche Products (Ireland) Ltd submitted a dossier examining the cost-effectiveness of alectinib for the first-line treatment of ALK-positive advanced NSCLC. The authorised dose for this indication

2019 National Centre for Pharmacoeconomics (Ireland)

15. Alectinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC).

Alectinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC). Alectinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC). EUnetHTA report - Repository of the LBI-HTA English | Browse - - - Alectinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC). EUnetHTA report Dental (...) and Pharmaceutical Benefits Agency (TLV), EUnetHTA and Main Association of Austrian Social Security Institutions (HVB), EUnetHTA and Agency for Quality and Accreditation in Health Care and Social Welfare (AAZ), EUnetHTA (2018): Alectinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC). EUnetHTA report. DSD: Horizon Scanning in Oncology 77. - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 4Mb Abstract

2019 Ludwig Boltzmann Institute of Health Technology Assessment

16. Delivering best practice lung cancer care - a guide for health professionals

Delivering best practice lung cancer care - a guide for health professionals This guide provides an overview of the Lung Cancer Framework, which can be accessed at: canceraustralia.gov.au/publications-and-resources/cancer-australia-publications/lung-cancer-framework A summary for health professionals Delivering best practice lung cancer care Cancer Australia’s Lung Cancer Framework: Principles for Best Practice Lung Cancer Care in Australia (the Lung Cancer Framework) is a national resource (...) for health professionals and service providers involved in the care and treatment of people affected by lung cancer. canceraustralia.gov.au The Lung Cancer Framework aims to improve the outcomes and experiences of people affected by lung cancer in Australia by supporting the uptake of five key principles in lung cancer care. Principles for best practice lung cancer care Cancer Australia’s Principles for best practice management of lung cancer in Australia have been informed by evidence from national

2018 Cancer Australia

17. Patient Navigation Models for Lung Cancer

Patient Navigation Models for Lung Cancer Rapid Evidence Product Patient Navigation Models for Lung Cancer eRapid Evidence Product Patient Navigation Models for Lung Cancer Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2017-00003-C Prepared by: Scientific Resource Center Portland, OR Investigators: Jennifer Gilbert, M.D., M.P.H. Stephanie Veazie, M.P.H. Kevin Joines, B.S (...) , other quality enhancement tools, or reimbursement or coverage policies, may not be stated or implied. Persons using assistive technology may not be able to fully access information in this report. For assistance contact epc@ahrq.hhs.gov. Suggested citation: Gilbert J, Veazie S, Joines K, Winchell K, Relevo R, Paynter R, Guise J-M. Patient Navigation Models for Lung Cancer. Rapid Evidence Product. (Prepared by Scientific Resource Center under Contract No. 290-2017-00003-C.) AHRQ Publication No. 18(19

2018 Effective Health Care Program (AHRQ)

18. Brigatinib (Alunbrig) - non-small cell lung cancer (NSCLC)

Brigatinib (Alunbrig) - non-small cell lung cancer (NSCLC) 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. EMA/674777/2018 EMEA/H/C/004248 Alunbrig (brigatinib) An overview of Alunbrig and why it is authorised in the EU What (...) is Alunbrig and what is it used for? Alunbrig is a cancer medicine that is used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC) who have been treated before with a cancer medicine called crizotinib. Alunbrig is used on its own and only if the NSCLC is ‘ALK-positive’, which means that the cancer cells have certain changes affecting the gene that makes a protein called ALK (anaplastic lymphoma kinase). Alunbrig contains the active substance brigatinib. How is Alunbrig

2018 European Medicines Agency - EPARs

19. Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation

Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search (...) above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Low-dose CT screening may be effective in reducing lung cancer mortality, but there is considerable uncertainty around effectiveness and value. {{author}} {{($index , , , , , , & . Tristan Snowsill 1, * , Huiqin Yang 1 , Ed Griffin 1 , Linda Long 1 , Jo Varley-Campbell 1 , Helen Coelho 1 , Sophie Robinson 1 , Chris Hyde 1, 2 1 Peninsula Technology Assessment

2018 NIHR HTA programme

20. Lorlatinib (Lorbrena) - To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer

Lorlatinib (Lorbrena) - To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer Drug Approval Package: LORBRENA (lorlatinib) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: LORBRENA (lorlatinib) Company: Pfizer, Inc. Application Number: 210868 Approval Date: 11/02/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter

2018 FDA - Drug Approval Package